Can tiny Mus­tang Bio com­pete on the CAR-T front with gi­ants like No­var­tis and Gilead? Man­ny Litch­man aims to find out

Now that No­var­tis and Gilead have picked up the first two ap­provals for CAR-T drugs, you can ex­pect to see ri­vals com­ing along who will probe for any weak­ness­es in their ap­proach, look­ing to com­pete on the next wave of per­son­al­ized cell ther­a­pies head­ed through the clin­ic.

The small crew at Mus­tang Bio — $MBIO, up 11% to­day — has some big am­bi­tions on that score, and to­day they’re adding some man­u­fac­tur­ing ca­pac­i­ty that the com­pa­ny be­lieves will be cen­tral to its abil­i­ty to even­tu­al­ly com­pete with these two gi­ants.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN